Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program - Sept. 1, 2020
Alexa
Alexa
Translational
Shannon
Shannon
Informatics
Yasmin
Yasmin
Bioinformatics
Yanyu
Yanyu
Protein Analytics
Jessica
Jessica
Discovery
Gosia
Gosia
Clinical
Jess
Jess
Administration
Karl
Karl
Protein Production
Jess
Jess
Pharmacology
Lorenzo
Lorenzo
Informatics
Courtney
Courtney
Clinical

DRIVEN BY SCIENCE. MOTIVATED BY PATIENTS.

 

Our approach to cancer immunotherapy prioritizes targets and identifies related biomarkers to match the right immunotherapy to the right patients – for meaningful and long-lasting benefit.

why we do what we do jounce
 
an innovative approach jounce
 
pipeline jounce
 
news jounce
 
life at Jounce jounce